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Background and Purpose—At least part of the failure in the transition from experimental to clinical studies in stroke has
been attributed to the imprecision introduced by problems in the design of experimental stroke studies. Using a
metaepidemiologic approach, we addressed the effect of randomization, blinding, and use of comorbid animals on the
estimate of how effectively therapeutic interventions reduce infarct size.
Methods—Electronic and manual searches were performed to identify meta-analyses that described interventions in
experimental stroke. For each meta-analysis thus identified, a reanalysis was conducted to estimate the impact of various
quality items on the estimate of efficacy, and these estimates were combined in a meta–meta-analysis to obtain a
summary measure of the impact of the various design characteristics.
Results—Thirteen meta-analyses that described outcomes in 15 635 animals were included. Studies that included
unblinded induction of ischemia reported effect sizes 13.1% (95% CI, 26.4% to 0.2%) greater than studies that included
blinding, and studies that included healthy animals instead of animals with comorbidities overstated the effect size by
11.5% (95% CI, 21.2% to 1.8%). No significant effect was found for randomization, blinded outcome assessment, or
high aggregate CAMARADES quality score.
Conclusions—We provide empirical evidence of bias in the design of studies, with studies that included unblinded
induction of ischemia or healthy animals overestimating the effectiveness of the intervention. This bias could account
for the failure in the transition from bench to bedside of stroke therapies. (Stroke. 2008;39:929-934.)
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During the past several decades, the modeling of stroke inanimals has led to great progress in our understanding of
the pathophysiologic mechanisms by which focal cerebral
ischemia kills brain cells.1,2 Despite the experimental identi-
fication of numerous therapeutic strategies for stroke therapy,
there has been an overall failure to validate their efficacy in
patients. The latest in a long list of randomized, clinical trials
with negative results3 in acute stroke (SAINT II, which used
a free-radical scavenger) showed no efficacy despite exten-
sive and superficially convincing preclinical data. These
failures demand a reexamination of the way experimental
stroke studies are conducted4 and fuel a debate concerning the
general predictive value of experimental modeling of this
complex disorder.5–7 The failure of bench-to-bedside progres-
sion may be due to problems in the way the experiments are
performed, or it may result from the use of unsuitable or
intrinsically flawed models; in other words, the problem may
lie either in the internal or the external validity of the
experiments.8
Bias is a key problem in internal validity, and 4 major types
have been described9: selection bias (creating groups with
different confounders; solved by randomization); perfor-
mance bias and detection bias (investigators respectively
treating or assessing more positively those subjects on the
treatment arm; controlled by blinding interventions and out-
come assessments); and attrition bias (dropouts of subjects
with a negative outcome not included in the final result;
solved by an intention-to-treat analysis or reporting of drop-
outs). A metaepidemiologic approach has been used in human
studies to find empirical evidence of bias in internal validity
(reviewed in Juni et al9), thereby exposing poor allocation
concealment and poor blinding of outcome assessment as
consistent sources of bias in human trials.
External validity is a matter of judgment that depends on
the characteristics of the subjects included, the setting, the
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treatment regimens, and the outcomes assessed. Perhaps 1 of
the most consistently cited problems in experimental stroke
research concerns the validity of extrapolating data from
young, healthy animals to elderly patients with frequent
comorbid conditions in human clinical trials.6,10
Although all of these biases have been addressed in
individual meta-analyses that have examined 1 intervention,
they have never been studied in their overall effect through-
out different interventions. Here we use a metaepidemiologic
approach to evaluate the evidence of bias in internal and
external validity of study designs in experimental stroke.
Methods
Inclusion Criteria and Outcome Measures
We included published or unpublished meta-analyses that reported
the efficacy of potential neuroprotectant therapies in experimental
focal cerebral ischemia wherein outcome was reported as a change in
infarct volume. We included data for all species and for all methods
of inducing focal cerebral ischemia. When data were unavailable for
extraction, authors of the original meta-analyses were contacted, or
data were extracted from the original studies.
Search
We searched for all pertinent meta-analyses on experimental stroke
with use of a computer-based search of MEDLINE (1966 to
February 2007) with the following subject headings: “cerebrovascu-
lar accident,” “meta-analysis,” “animal experimentation,” and “mod-
els, animal” and the following text words: “stroke,” “cerebrovascu-
lar,” “meta analysis,” “meta-analysis,” “systematic review,” and
“animals.” No language constraints were applied. Citations of all
selected studies were searched for additional meta-analyses. Rele-
vant published and unpublished studies were also identified from the
CAMARADES web page,11 from review articles,4 and by
contacting authors.
Data Extraction and Statistical Analysis
The study intended to evaluate the influence of quality variables in
experimental stroke, irrespective of the therapy used. The quality
characteristics studied included aspects that referred to the internal
validity of the studies, such as randomized generation of the
sequence of allocation, blinded induction of ischemia (allocation
concealment), and blinded assessment of outcome. Studies had to
explicitly report being randomized, using blinded induction, or using
blinded assessment; if not, they were considered as not having the
quality studied. This was obtained from the original meta-analysis, or
if not reported, from the individual study. We also looked at certain
aspects of external validity of the studies, particularly the effect of
the use of animals with comorbidities, ie, old age, hypertension,
hyperglycemia, or diabetes. We explored the overall effect of
study quality by dichotomizing studies into those scoring 4 or less
(low quality) or more than 4 (high quality) on the CAMARADES
study quality score (Macleod et al12; see supplemental Table I for
definitions, available at http://stroke.ahajournals.org), a widely used
score based on the STAIR criteria.13 Attrition bias indicators (such as
the reporting of excluded animals due to death during intervention or
to prespecified inclusion or exclusion criteria) were not extracted,
because a preliminary overview of included studies showed that such
indicators were not reported with sufficient frequency to allow such
an analysis.
For each study, infarct size in treatment and control groups was
calculated and the normalized mean treatment effect (percentage
reduction in infarct volume in the treatment group; NMD) and
standard deviations were calculated. We chose this approach, in
preference to standardized mean difference (SMD) meta-analysis,
because NMD analysis appears to perform better when the size of
individual experiments is small, presumably because the observed
variance used for weighting is a less precise estimate of the
population variance than is the case for larger studies.14 Furthermore,
there is a potential confounding effect of weighting studies according
to variance. Given first, that the observed variance represents a
combination of measurement error in addition to inherent or biologic
variance, and second, that low study quality is likely to be associated
with high measurement error, a weighting system that included
measurement error might minimize the impact of low-quality studies
and therefore obscure the effects of interest. To explore whether this
was indeed the case, all analyses were repeated with Hedges’ g
SMD.15
A 2-level analysis was performed by a “meta–meta-analytic”
approach with a random-effects model to allow for within– and
between–meta-analysis heterogeneity. In brief, for each meta-analy-
sis identified and for each variable, included studies were divided
into 2 groups according to the relevant quality item (eg, blinding).
Meta-analyses in which all studies were in 1 arm of the analysis (eg,
all nonblinded) were not included in this part of the analysis. Infarct
sizes for each study were extracted and then pooled independently
for each category described by NMD analysis and a random-effects
model. Two effect sizes, each with its variance, were calculated for
each meta-analysis, 1 corresponding to efficacy pooled from those
studies, which had the characteristic of interest (eg, blinded), and the
other for those studies that did not (eg, nonblinded).
The second-order analysis involved pooling the results of the
previous analysis to describe the effect of the methodologic quality
item in general rather than in the context of a specific therapy. The
use of a random-effects model at this stage allows for between–meta-
analysis heterogeneity and does not rely on the assumption of a
constant effect of the variable studied in the different therapies.
Heterogeneity was tested by the 2 test. Analyses were performed
with Cochrane’s RevMan software for meta-analysis.16 A probability
value 0.05 was considered statistically significant.
Results
Electronic search identified 9 studies from MEDLINE,12,17–24
1 study from a reference,25 and 1 study from the CAMA-
RADES web page.26 Two studies unpublished at the time of
the search were provided by 1 of the authors (27 and Sena and
Macleod, unpublished data, 2007); this gave a total of 13
meta-analyses that described outcome in 15 635 animals (the
Table).
Randomization
Eleven meta-analyses involving 14 804 animals assessed the
effect of randomization in experimental stroke. Two meta-
analyses were excluded because none of their studies was
Table. Meta-Analyses Included
Meta-Analysis Intervention
Nava-Ocampo et al, 200025 Glutamate release blockers
Horn et al, 200117 Nimodipine
Macleod et al, 200412 Nicotinamide
Macleod et al, 200518 FK506
Macleod et al, 200519 Melatonin
Willmot et al, 200520 Nitric oxide synthase inhibitors
Willmot et al, 200521 Nitric oxide donors and L-arginine
Gibson et al, 200622 Estrogens
Perel et al, 200723 Tissue-type plasminogen activator
Sena et al, 200724 Tirilazad
Wheble et al26 Piracetam and Piracetam-like agent
Sena and Macleod (unpublished) Interleukin-1 receptor antagonist
van der Worp27 Hypothermia
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described as being randomized.17,25 No significant effect of
randomization was found (NMD, 7.0%; 95% CI, 15.1%
to 1.2%; Figure 1).
Blinded Induction of Ischemia
Seven meta-analyses involving 8921 animals assessed the
effect of blinding of the induction of ischemia; 6 meta-anal-
yses were excluded because all of their studies were de-
scribed as nonblinded.12,18,20,22,25,26 Studies not reporting
blinded induction of ischemia had a significant overestima-
tion of the effect of the therapy being studied, overestimating
the effect size by 13.3% (95% CI, 0.2% to 26.4%; Figure 2).
Blinded Assessment of Outcome
Thirteen meta-analyses involving 15 635 animals assessed
the effect of blinding the assessment of outcome. No effect of
blinding the assessment of infarct size was found (NMD,
2.1%; 95% CI, 8.3% to 4.0%; Figure 3).
Comorbidity
Ten meta-analyses were included for assessing the effect of
using animals with comorbidities, with 13 639 animals. Three
meta-analyses were not included because none of their
studies included animals with comorbidities19,25 (and Sena
and Macleod, unpublished data, 2007). As shown in Figure 4,
studies that included healthy animals tended to overestimate
the normalized infarct size by 11.5% (NMD; 95% CI, 1.9% to
21.2%).
Effect of Study Quality
Finally, we compared high-quality and low-quality studies,
dichotomized according to a score based on STAIR criteria.
Twelve meta-analyses with 14 886 animals were included,
and 1 meta-analysis had to be excluded because it included no
high-quality studies.25 Figure 5 shows that no significant
influence of “quality” was found (NMD, 3.4%; 95% CI,
8.5% to 1.7%).
Heterogeneity was significant in all of the aforementioned
analyses, except for the effect of quality. All analyses were
performed again with the SMD approach, and the results were
broadly similar. Specifically, the effect of comorbidity was
no longer significant (SMD, 0.20; 95% CI, 0.10 to 0.51).
Heterogeneity was lower in all SMD analyses than in the
corresponding NMD analyses.
Discussion
Herein we show for the first time the feasibility and utility of
a metaepidemiologic approach in the assessment of the
presence of bias in the design of experimental stroke studies.
We provide empirical evidence on the effect of design
characteristics in experimental stroke research that could
partly account for the failure in the transition from bench to
bedside. Previous individual meta-analyses have included
stratified analyses by dividing their studies according to
similar quality variables that were used in our approach and
looking at their impact, but to our knowledge, this is the first
time that this issue has been studied with respect to different
interventions.
One of the strengths of our approach is the use of a
random-effects model; this does not require the assumption of
a constant effect of the variable studied in different interven-
tions (between–meta-analysis heterogeneity).28 However, by
allowing more variance in its calculations, this method
compromises statistical power.
Randomization had no consistent effect in our analysis.
When one considers that animals used in experimental studies
represent a very homogeneous population in terms of same
strain, sex, age, weight, etc, the possibility of selection bias
seems small compared with the more heterogeneous human
clinical situation. However, this is similar to findings from
Figure 2. Effect of blinding the induction
of ischemia on effectiveness of stroke
treatment intervention in experimental
(animal model) studies. Abbreviations are
as in the legend to Figure 1.
Figure 1. Effect of randomization on
effectiveness of stroke treatment interven-
tion in experimental (animal model) stud-
ies. IL1-ra indicates interleukin-1 receptor
antagonist; NOS, nitric oxide synthase;
and tPA, tissue-type plasminogen
activator.
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some human studies, wherein concealment of the sequence of
randomization appeared to be more important.9 Inadequate
concealment of the sequence of randomization in human
studies may lead to selection bias, because investigators may
consciously or unconsciously select patients to 1 or the other
arm according to their characteristics and likely prognosis.
This concern is rarely addressed in the experimental stroke
literature. One of the factors most likely to influence outcome
in experimental stroke is the care and enthusiasm of induction
of ischemia and the precise duration of that ischemia;
therefore, blinding the investigator to group assignment
(allocation concealment, or blinded induction of ischemia) is
crucial and meets the same purpose as concealment of
allocation sequence in human studies. Indeed, we have shown
a significant overstatement of efficacy when induction of
ischemia was unblinded.
Blinding the assessment of outcome had no effect on
efficacy when outcome was measured as infarct size. Perhaps
as a result of the use of semiautomated measurement tech-
niques, infarct size appeared to be a robust and relatively
objective measure of outcome less prone to observer bias; the
performance of other outcome measures, for instance, neu-
robehavioral scores, is not known.
Interestingly, studies that included animals with comor-
bidities and those that included healthy animals differed by
10% in their effect size, a difference similar to the one
found in those that used blinded induction of ischemia
compared with those that were unblinded. Because most
interventions reported a decrease of 30% to 40% of the
control infarct size, this result seems to be of great
importance.
Finally, despite an effect of 2 components of the study
score, we found no apparent difference between high- and
low-quality studies. Previous individual meta-analyses on neu-
roprotectant interventions did look at the difference in infarct
size according to a quality scale and found varying results,
including a decreased effect with increasing quality,18,22 no
clear relation,17,19 and even a decrease in effect with poor
quality.20 All of these studies had less power than our
approach, because they looked at only 1 intervention instead
of analyzing and pooling several different therapies. One
other study reported the effect of a similar quality scale in the
effect size by pooling several interventions, and importantly,
although using a different approach, O’Collins et al29 found
no difference between the effect sizes of studies defined as
high compared with low quality. There are a number of
possible explanations for this. First, the bias from different
quality characteristics might operate in different directions
(some increasing and others reducing the estimate of effi-
cacy). However, in univariate analysis, there is no evidence
for this (Sena and Macleod, unpublished observations). Sec-
ond, the pooling of multiple characteristics in a global quality
score might dilute the effects of important predictors of bias.
The interpretation of quality data as existing on an ordinal
scale with the same weight attributed to different aspects of
methodologic quality is clearly a highly simplistic view of the
complex entity of study quality.4,30,31 Finally, dichotomiza-
tion of scales for statistical analysis introduces bias, and
minor changes in cutoffs for dichotomization may strongly
affect the result of the analysis. We propose that qualitative
scales might be most useful as a “checklist” to qualitatively
describe different studies, rather than as a quantitative marker
of overall quality.
Figure 4. Effect of including animals with
comorbid conditions on effectiveness of
stroke treatment intervention in experi-
mental (animal model) studies. Abbrevia-
tions are as in the legend to Figure 1.
Figure 3. Effect of blinding the assess-
ment of outcome on effectiveness of
stroke treatment intervention in experi-
mental (animal model) studies. Glut indi-
cates glutamate. Other abbreviations are
as in the legend to Figure 1.
932 Stroke March 2008
Our approach has a number of potential weaknesses. The
statistical power of this approach is unknown, and we might
falsely conclude that a potential source of bias is unimportant
when in fact it is. To avoid the problem of multiple compar-
isons, a finite number of variables were included, but many
important variables were excluded, particularly with respect
to the external validity of the studies, such as drug dosing
time or timing of the assessment of outcome. Specifically,
these 2 variables were balanced in our studies and did not
confound the results, but their impact remains to be assessed
in future studies. Furthermore, this was essentially a univar-
iate approach; interactions between different potential
sources of bias or between potential sources of bias and other
attributes of contributing studies (such as the drug or species
used, drug dose, etc) were not captured in this analysis, and a
multivariate approach would be required.
In line with similar meta-epidemiological studies of clini-
cal meta-analyses,9,32 our current study looked at the quality
reported by the studies and assumed that quality was inade-
quate unless information to the contrary was provided (the
“guilty until proved innocent” approach), and therefore, some
studies might have been deemed as not having quality when
the problem was of underreporting. Although we cannot rule
out the possibility that including “real” quality variables
instead of reported quality variables would have affected our
results, there is some evidence that the frequency of under-
reporting quality variables is low, and therefore also the
probability of having an impact in our analysis.33
Infarct size is certainly a widespread outcome reported in
experimental stroke, but valid doubts exist regarding how
useful this outcome is for human studies. In response to this
problem, a number of articles have reported functional
neurologic outcomes, and STAIR criteria explicitly encour-
age their use. It would be interesting to study the impact of
these quality variables on this type of outcome. Unfortu-
nately, the available published data do not seem sufficient to
perform this type of analysis. Analysis of the available data
resulted in few studies included with effect sizes, with wide
CIs and no significant results.
Perhaps the most striking result of this study is the effect
that methodologic variables can have on the final outcome.
Editors of leading journals should be aware of this factor and
consider requesting potential authors to explicitly disclose
their study design, as well as aim to publish only high-quality
studies, thus helping to bring the quality of experimental
studies up to the current level of clinical trial reporting.
Unfortunately, although we have seen in recent years an
improvement in the reporting of compliance with legislative
requirements promulgated by STAIR, there has been no
substantial improvement in study quality.33 We hope that our
revelation of the importance of these issues contributes to a
change in their practice.
Conclusions
Blinding the induction of ischemia and the use of comorbid
animals each significantly affected the estimate of how
effective an intervention was in experimental stroke; Effect
sizes in studies with or without either of these characteristics
differed by10% in their effect size. Given an effect size for
most interventions of between 30% and 40%, this result is of
substantial importance. Such design characteristics can intro-
duce bias in experimental stroke studies that can at least
partly account for the failure in the transition from bench to
bedside.
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